IFM Therapeutics has lined up another pact with a big pharma company, and it’s the second one in less than a year with Novartis.

Boston-based IFM Therapeutics announced Thursday that Novartis (NYSE: NVS) has agreed to pay the research and development costs of IFM Due, a subsidiary developing immunotherapies for inflammatory and autoimmune diseases. Novartis gains an exclusive option to acquire IFM Due.

The companies did not disclose how much Novartis is paying up front to kick off the partnership. But if the Basel, Switzerland pharmaceutical giant exercises its option to acquire IFM Due, the biotech’s shareholders will receive up… Read more »